Artificial Tissue System for Implantable Sensor Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Implantable sensors, such as glucose sensors, face significant challenges due to acute and chronic tissue reactions, leading to short lifespan and loss of function in vivo, primarily caused by tissue injury, inflammation, and foreign body reactions, which current coatings and drug delivery systems are unable to effectively mitigate.
Innovation Solution
An artificial tissue system (ATS) is introduced, comprising cells and a matrix material that promotes biological interaction with implantable devices, including genetically engineered cells and tissue response modifiers, to enhance integration and extend the lifespan of implanted devices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional sensor coatings are used to hide the sensor from tissue reactions, then the sensor can be implanted, but the sensor still loses function quickly due to immune detection and tissue destruction
Solution Approach 1:
The patent introduces an artificial tissue system as an intermediary layer between the sensor and host tissue. This ATS includes cells (such as fibroblasts, macrophages, or stem cells) and extracellular matrix components that mediate the interaction between the foreign sensor and host tissue, transforming the acute foreign body reaction into a chronic stable interface. The ATS acts as a biological buffer that prevents direct tissue damage while maintaining sensor function.
Solution Approach 2:
The invention employs composite biological materials comprising multiple cell types, extracellular matrix proteins (collagen, fibronectin, laminin), and growth factors assembled into a functional tissue structure. This composite artificial tissue system provides both structural support and biological activity to promote sensor integration and prevent degradation, overcoming the limitations of simple coatings.
2Reliability
If bioactive drugs and peptides are incorporated into sensor coatings, then some tissue reactions are reduced, but the bioactive agents are masked or degraded by intense tissue reactions and limited quantities can be incorporated
Solution Approach 1:
The patent transitions from two-dimensional sensor coatings to three-dimensional artificial tissue structures. The ATS creates a volumetric environment that can accommodate and protect large quantities of bioactive agents throughout its structure, rather than being limited to surface coating capacity. This dimensional expansion allows extensive incorporation of therapeutic molecules while maintaining their activity through the protected 3D architecture.
Solution Approach 2:
The artificial tissue system serves as a protective intermediary that shields bioactive agents from degradation by intense tissue reactions. The cells and matrix components of the ATS create a biological barrier that preserves the activity of incorporated drugs and peptides, preventing them from being masked or degraded by host immune responses.
3Productivity
If traditional drug delivery systems are used near the sensor, then drug delivery is achieved, but foreign body tissue reactions to the drug delivery system have negative bystander effects on the sensor
Solution Approach 1:
The invention merges the drug delivery function with the artificial tissue system itself, creating an integrated system where the ATS serves both as structural support and as the delivery mechanism. The cells and matrix components of the ATS can be engineered to release bioactive agents in a controlled manner, eliminating the need for separate drug delivery devices that would provoke additional foreign body reactions.
Data Source
AI summary
An implant system and a method for controlling the natural and artificial microenvironments surrounding an implanted device using an artificial tissue system (ATS) and includes methods of diagnostic and testing related thereto. The ATS, among other things, induce better integration, function, and extended lifespan of the devices at the site of implantation. The ATS includes cells, such as naturally occurring, engineered, and/or artificial cells; matrices such as natural, engineered, artificial and/or hybrid matrices; tissue response modifiers (TRM); and/or cell response modifiers (CRM). The specific composition of the ATS is based on the nature of the tissue in which ATS-device combination is implanted and the nature of the implant device, as well as the required function and lifespan of the implanted device. Additionally, the ATS, as well as ATSdevice combinations can be utilized in vitro to aid in the design of improved ATS, devices and ATS-device combinations for in \>ivo uses.